+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

C-C Chemokine Receptor Type 5 - Pipeline Review, H2 2019

  • ID: 4866580
  • Drug Pipelines
  • November 2019
  • Region: Global
  • 90 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Allergan Plc
  • Bristol-Myers Squibb Co
  • Cytodyn Inc
  • Merck & Co Inc
  • Novartis AG
  • MORE
C-C Chemokine Receptor Type 5 - Pipeline Review, H2 2019

Summary

According to the recently published report 'C-C Chemokine Receptor Type 5 - Pipeline Review, H2 2019'; C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) pipeline Target constitutes close to 15 molecules. Out of which approximately 10 molecules are developed by companies and remaining by the universities/institutes.

C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) - C-C chemokine receptor type 5 (CCR5) also known as CD195, is a surface protein located on the plasma membrane of white blood cells and is encoded by CCR5 gene. This receptor binds and responds to a variety of chemokines (CCL3, CCL4, CCL5, CCL3L1). This protein is expressed by T cells and macrophages, and is known to be an important co-receptor for macrophage-tropic virus, including HIV, to enter host cells. It plays a role in granulocyte lineage proliferation and differentiation.

The report 'C-C Chemokine Receptor Type 5 - Pipeline Review, H2 2019' outlays comprehensive information on the C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 1, 1, 3, 1, 2 and 2 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 4 and 1 molecules, respectively.

Report covers products from therapy areas Infectious Disease, Oncology, Gastrointestinal, Respiratory, Central Nervous System and Immunology which include indications Human Immunodeficiency Virus (HIV) Infections (AIDS), Metastatic Colorectal Cancer, Non-Alcoholic Steatohepatitis (NASH), Chronic Obstructive Pulmonary Disease (COPD), Liver Fibrosis, Bone Metastasis, Colorectal Cancer, Gastric Cancer, Graft Versus Host Disease (GVHD), Hepatocellular Carcinoma, Liver Cancer, Lung Cancer, Melanoma, Metastatic Pancreatic Cancer, Multiple Sclerosis, Non-Small Cell Lung Cancer, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Primary Sclerosing Cholangitis, Prostate Cancer and Triple-Negative Breast Cancer (TNBC).

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The report provides a snapshot of the global therapeutic landscape for C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5)
  • The report reviews C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) targeted therapeutics and enlists all their major and minor projects
  • The report assesses C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) targeted therapeutics
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Allergan Plc
  • Bristol-Myers Squibb Co
  • Cytodyn Inc
  • Merck & Co Inc
  • Novartis AG
  • MORE
Introduction
Report Coverage
C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) - Overview
C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) - Companies Involved in Therapeutics Development
Allergan Plc
American Gene Technologies International Inc
Auritec Pharmaceuticals Inc
Bristol-Myers Squibb Co
Cytodyn Inc
Merck & Co Inc
Novartis AG
Orion Biotechnology Canada Ltd
C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) - Drug Profiles
(cenicriviroc + tropifexor) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(emtricitabine + tenofovir disoproxil fumarate) + maraviroc SR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AG-1105 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BMS-813160 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cenicriviroc - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs to Antagonize CCR5 for Chronic Obstructive Pulmonary Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DS-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DS-004 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DS-005 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
leronlimab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Antagonize CCR5 for Chronic Obstructive Pulmonary Disease (COPD) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OB-002H - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OB-002M - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OB-002O - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
vicriviroc - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) - Dormant Products
C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) - Discontinued Products
C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) - Product Development Milestones
Featured News & Press Releases
Nov 12, 2019: CytoDyn receives IRB approval to proceed with compassionate use of leronlimab for patients with triple-negative breast cancer
Nov 11, 2019: First patient in CytoDyn’s triple-negative metastatic breast cancer trial shows significant reduction in circulating tumor cells (CTC) and reduced tumor size
Nov 06, 2019: American Gene Technologies hosts celebration event for its first IND submission (For HIV) to the Food and Drug Administration (FDA)
Oct 24, 2019: GeoVax Vaccine to be used in a phase 1 trial of genetically modified autologous cell therapy for HIV
Oct 18, 2019: IND application submission to FDA for phase 1 trial Of genetically modified autologous cell therapy for HIV announced by American Gene Technologies
Oct 11, 2019: CytoDyn to present at The MicroCap Rodeo Conference
Oct 03, 2019: CytoDyn to assess leronlimab in Phase II NASH trial
Oct 01, 2019: American Gene Technologies to present at 2019 Cell & Gene Meeting on the Mesa
Sep 27, 2019: CytoDyn treats first patient in phase 1b/2 clinical Trial with Leronlimab (PRO 140) for patients with treatment-Naïve, Metastatic Triple-Negative Breast Cancer
Sep 12, 2019: Orion Biotechnology to initiate clinical trials of its Innovative Microbicide Gel for HIV prevention
Sep 09, 2019: CytoDyn announces FDA clearance to proceed with phase 2 Study of Leronlimab (PRO 140) and Regorafenib as a combination therapy for metastatic colorectal cancer
Sep 04, 2019: CytoDyn files an IND and a phase 2 protocol with the FDA for the treatment of NASH with Leronlimab
Aug 29, 2019: CytoDyn to present at RHK Capital 2019 Disruptive Growth Conference
Aug 14, 2019: CytoDyn provides update on dose escalating trial with Leronlimab for HIV Monotherapy for a potential pivotal trial
Aug 08, 2019: CytoDyn files a phase 2 protocol with the FDA for Leronlimab (PRO 140) and Regorafenib as a combination therapy for metastatic colorectal cancer
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Allergan Plc, H2 2019
Pipeline by American Gene Technologies International Inc, H2 2019
Pipeline by Auritec Pharmaceuticals Inc, H2 2019
Pipeline by Bristol-Myers Squibb Co, H2 2019
Pipeline by Cytodyn Inc, H2 2019
Pipeline by Merck & Co Inc, H2 2019
Pipeline by Novartis AG, H2 2019
Pipeline by Orion Biotechnology Canada Ltd, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Dormant Products, H2 2019 (Contd..2), H2 2019
Discontinued Products, H2 2019

List of Figures
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Allergan Plc
  • American Gene Technologies International Inc
  • Auritec Pharmaceuticals Inc
  • Bristol-Myers Squibb Co
  • Cytodyn Inc
  • Merck & Co Inc
  • Novartis AG
  • Orion Biotechnology Canada Ltd
Note: Product cover images may vary from those shown
Adroll
adroll